Multiple Myeloma

A nurse practitioner and two hematologic oncologists outline diagnosis and staging practices for patients with multiple myeloma.

Explore the critical aspects of counseling patients on the expectations and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) associated with CAR-T therapy.

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

Dr Dhakal outlines the FDA-approved CAR T-cell therapy products for patients with multiple myeloma who have undergone at least four prior lines of treatment, emphasizing a focus on individualized decision-making when selecting patients for CAR-T.

Joselle Cook, M.B.B.S., presents the case of a 62-year-old woman with high-risk multiple myeloma to the panel for discussion.

Comprehensive insights on quadruplet therapy regimens and the risk stratification process for patients with multiple myeloma.

A panel of experts on multiple myeloma discuss newly diagnosed patients and factors that determine transplant eligibility.

Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.

Expert panelists review the complex decision-making process between CAR-T and BCMA bispecific therapies in the management of relapsed myeloma, discussing patient-specific factors and relative risks and benefits.

The expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.

A complex case study in multiple myeloma management, exploring treatment sequencing options for a patient with a long history of disease and multiple lines of therapy.

Multiple myeloma–treating oncologists provide comprehensive insights on deciding between bispecific antibody monotherapy, combination therapy, and CAR T-cell therapy.

Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments.

Experts in the field of multiple myeloma gathered to discusses treatment options including bispecific antibodies CAR T-cell therapy, and the importance of collaborative decision-making across clinics.

A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.

Joselle Cook, M.B.B.S., explains that she believes that elderly patients with relapsed/refractory multiple myeloma can still use bispecific therapies, though more objective data on frailty is needed.

Drs Costa, Dhakal, and Cook discuss managing the unique toxicities of bispecific antibodies in patients with relapsed/refractory multiple myeloma such as infections requiring prophylaxis and supportive care, and quality-of-life complaints like taste changes and skin issues.

In a recent Training Academy, experts discussed how to incorporate bispecific antibodies into patients with multiple myeloma.

Gain insight into strategies for monitoring for ICANS and CRS in myeloma treatment, including inpatient and outpatient administration, tocilizumab, dexamethasone, and impact on patient care.

The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.

Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.

Key opinion leaders share their insight on managing adverse events in myeloma treatment, including dose adjustments and prophylactic strategies to improve outcomes and patient quality of life.

The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.

Experts in the multiple myeloma space met to discuss the treatment and monitoring after bispecific antibodies.

Joselle Cook, M.B.B.S., and Luciano Costa, MD, note promising trials investigating combination bispecific antibody therapies for patients with relapsed/refractory multiple myeloma.

Drs Luciano Costa and Binod Dhakal discuss combining bispecific antibodies with gamma secretase inhibitors for the treatment of relapsed/refractory multiple myeloma, but trials show limited benefit and added toxicity; more promising are combinations with immunomodulators like isatuximab.

Overview of challenges in managing adverse events associated with bispecific therapy in multiple myeloma, including dysgeusia, skin toxicity, and nail changes patients may experience.

Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.

Experts share how the availability of three new bispecific therapies has transformed myeloma patient care, offering a lifeline to those previously without treatment options and showcasing positive responses in various patient populations.

Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.